Changeset 1510 for qrda/C0Q/trunk/kids/C0Q-1_SEQ-003_PAT-003.KID
- Timestamp:
- Aug 6, 2012, 2:24:18 PM (12 years ago)
- File:
-
- 1 edited
-
qrda/C0Q/trunk/kids/C0Q-1_SEQ-003_PAT-003.KID (modified) (73 diffs)
Legend:
- Unmodified
- Added
- Removed
-
qrda/C0Q/trunk/kids/C0Q-1_SEQ-003_PAT-003.KID
r1508 r1510 1 KIDS Distribution saved on Aug 0 3, 2012@17:09:591 KIDS Distribution saved on Aug 06, 2012@11:32:48 2 2 QUALITY MEASURES 1.0 PATCH 3 3 3 **KIDS**:C0Q*1.0*3^ … … 6 6 C0Q*1.0*3 7 7 "BLD",7936,0) 8 C0Q*1.0*3^QUALITY MEASURES^0^312080 3^y8 C0Q*1.0*3^QUALITY MEASURES^0^3120806^y 9 9 "BLD",7936,1,0) 10 10 ^^155^155^3120803^ … … 328 328 329 329 "BLD",7936,6.3) 330 1 1330 12 331 331 "BLD",7936,"ABPKG") 332 332 n … … 441 441 "DATA",1130580001.101,4,6,3,0) 442 442 using a certified/qualified electronic health record (EHR) 443 "DATA",1130580001.101,4,7)444 ^^^^445 443 "DATA",1130580001.101,6,0) 446 444 PQRI MEASURE 47^^^2.16.840.1.113883.3.249.11.52 … … 463 461 "DATA",1130580001.101,6,6,5,0) 464 462 or provide an advance care plan. 465 "DATA",1130580001.101,6,7)466 ^^^^467 463 "DATA",1130580001.101,7,0) 468 464 PQRI MEASURE 48^^^2.16.840.1.113883.3.249.11.53 … … 481 477 "DATA",1130580001.101,7,6,3,0) 482 478 absence of urinary incontinence within 12 months 483 "DATA",1130580001.101,7,7)484 ^^^^485 479 "DATA",1130580001.101,12,0) 486 480 MU EP NQF 0043^^^2.16.840.1.113883.3.249.11.8 … … 515 509 "DATA",1130580001.101,14,6,3,0) 516 510 within 12 months before the end of the measurement period 517 "DATA",1130580001.101,14,7)518 ^^^^519 511 "DATA",1130580001.101,16,0) 520 512 PQRI MEASURE 173^^^2.16.840.1.113883.3.249.11.55 … … 531 523 "DATA",1130580001.101,16,6,2,0) 532 524 ed for unhealthy alcohol use using a systematic method within 24 months 533 "DATA",1130580001.101,16,7)534 ^^^^535 525 "DATA",1130580001.101,23,0) 536 MU HOS NQF 0495 ^^526 MU HOS NQF 0495 537 527 "DATA",1130580001.101,23,1) 538 528 ED THROUGHPUT ARRIVAL TO DEPARTURE … … 550 540 NQF0495^^^^^^88^165 551 541 "DATA",1130580001.101,24,0) 552 MU HOS NQF 0497 ^^542 MU HOS NQF 0497 553 543 "DATA",1130580001.101,24,1) 554 544 ED THROUGHPUT ADMITTING DECISION TO DEPARTURE … … 566 556 NQF0497^^^^^^90^168 567 557 "DATA",1130580001.101,25,0) 568 MU HOS NQF 0435 ^^558 MU HOS NQF 0435 569 559 "DATA",1130580001.101,25,1) 570 560 Ischemic stroke.Discharge on anti-thrombotics … … 580 570 NQF0435^^^^^^114^115 581 571 "DATA",1130580001.101,26,0) 582 MU HOS NQF 0436 ^^572 MU HOS NQF 0436 583 573 "DATA",1130580001.101,26,1) 584 574 Ischemic stroke.Anticoagulation for A-fib/flutter … … 594 584 NQF0436^^^^^^116^117 595 585 "DATA",1130580001.101,27,0) 596 MU HOS NQF 0437 ^^586 MU HOS NQF 0437 597 587 "DATA",1130580001.101,27,1) 598 588 Ischemic stroke.Thrombolytic therapy for patients arriving within 2 hours of symptom onset … … 610 600 NQF0437^^^^^^119^118 611 601 "DATA",1130580001.101,28,0) 612 MU HOS NQF 0438 ^^602 MU HOS NQF 0438 613 603 "DATA",1130580001.101,28,1) 614 604 Ischemic or hemorrhagic stroke.Antithrombotic therapy by day 2 … … 624 614 NQF0438^^^^^^120^121 625 615 "DATA",1130580001.101,29,0) 626 MU HOS NQF 0439 ^^616 MU HOS NQF 0439 627 617 "DATA",1130580001.101,29,1) 628 618 Ischemic stroke.Discharge on statins … … 640 630 NQF0439^^^^^^122^123 641 631 "DATA",1130580001.101,30,0) 642 MU HOS NQF 0440 ^^632 MU HOS NQF 0440 643 633 "DATA",1130580001.101,30,1) 644 634 Ischemic or hemorrhagic stroke.Stroke education … … 660 650 NQF0440^^^^^^124^125 661 651 "DATA",1130580001.101,31,0) 662 MU HOS NQF 0441 ^^652 MU HOS NQF 0441 663 653 "DATA",1130580001.101,31,1) 664 654 Ischemic or hemorrhagic stroke.Rehabilitation assessment … … 674 664 NQF0441^^^^^^126^127 675 665 "DATA",1130580001.101,32,0) 676 MU HOS NQF 0371 ^^666 MU HOS NQF 0371 677 667 "DATA",1130580001.101,32,1) 678 668 VTE prophylaxis within 24 hours of arrival … … 692 682 NQF0371^^^^^^69^67 693 683 "DATA",1130580001.101,33,0) 694 MU HOS NQF 0372 ^^684 MU HOS NQF 0372 695 685 "DATA",1130580001.101,33,1) 696 686 ICU VTE prophylaxis … … 712 702 NQF0372^^^^^^128^71 713 703 "DATA",1130580001.101,34,0) 714 MU HOS NQF 0373 ^^704 MU HOS NQF 0373 715 705 "DATA",1130580001.101,34,1) 716 706 Anticoagulation overlap therapy … … 738 728 NQF0373^^^^^^129^144 739 729 "DATA",1130580001.101,35,0) 740 MU HOS NQF 0374 ^^730 MU HOS NQF 0374 741 731 "DATA",1130580001.101,35,1) 742 732 Platelet monitoring on unfractionated heparin … … 768 758 NQF0374^^^^^^145^146 769 759 "DATA",1130580001.101,36,0) 770 MU HOS NQF 0375 ^^760 MU HOS NQF 0375 771 761 "DATA",1130580001.101,36,1) 772 762 VTE discharge instructions … … 800 790 NQF0375^^^^^^147^156 801 791 "DATA",1130580001.101,37,0) 802 MU HOS NQF 0376 ^^792 MU HOS NQF 0376 803 793 "DATA",1130580001.101,37,1) 804 794 Incidence of potentially preventable VTE … … 908 898 NQF0041^^^^^^242^243 909 899 "DATA",1130580001.101,43,0) 910 MU EP NQF 0024 ^^900 MU EP NQF 0024 911 901 "DATA",1130580001.101,43,1) 912 902 NQF0024 Weight Assessment and Counseling for Children and Adolescents (ALL) … … 968 958 combination rates. 969 959 "DATA",1130580001.101,44,7) 970 NQF0038 ^^^^960 NQF0038 971 961 "DATA",1130580001.101,45,0) 972 962 MU EP NQF 0059^^^2.16.840.1.113883.3.249.11.2 … … 1036 1026 prescribed ACE inhibitor or ARB therapy 1037 1027 "DATA",1130580001.101,48,7) 1038 NQF0081 ^^^^1028 NQF0081 1039 1029 "DATA",1130580001.101,49,0) 1040 1030 MU EP NQF 0070^^^2.16.840.1.113883.3.249.11.6 … … 1070 1060 mammogram to screen for breast cancer 1071 1061 "DATA",1130580001.101,50,7) 1072 NQF0031 ^^^^1062 NQF0031 1073 1063 "DATA",1130580001.101,51,0) 1074 1064 MU EP NQF 0034^^^2.16.840.1.113883.3.249.11.10 … … 1086 1076 colorectal cancer. 1087 1077 "DATA",1130580001.101,51,7) 1088 NQF0034 ^^^^1078 NQF0034 1089 1079 "DATA",1130580001.101,52,0) 1090 MU EP NQF 0067 ^^1080 MU EP NQF 0067 1091 1081 "DATA",1130580001.101,52,1) 1092 1082 Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD … … 1100 1090 diagnosis of CAD who were prescribed oral antiplatelet therapy. 1101 1091 "DATA",1130580001.101,52,7) 1102 NQF0067 ^^^^1092 NQF0067 1103 1093 "DATA",1130580001.101,53,0) 1104 MU EP NQF 0083 ^^1094 MU EP NQF 0083 1105 1095 "DATA",1130580001.101,53,1) 1106 1096 Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) … … 1116 1106 prescribed beta-blocker therapy 1117 1107 "DATA",1130580001.101,53,7) 1118 NQF0083 ^^^^1108 NQF0083 1119 1109 "DATA",1130580001.101,54,0) 1120 MU EP NQF 0105 ^^1110 MU EP NQF 0105 1121 1111 "DATA",1130580001.101,54,1) 1122 1112 Anti-depressant medication management: (a) Effective Acute Phase Treatment,(b)Effective Continuation Phase Treatment … … 1134 1124 antidepressant medication treatment. 1135 1125 "DATA",1130580001.101,54,7) 1136 NQF0105 ^^^^1126 NQF0105 1137 1127 "DATA",1130580001.101,55,0) 1138 MU EP NQF 0086 ^^1128 MU EP NQF 0086 1139 1129 "DATA",1130580001.101,55,1) 1140 1130 Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation … … 1152 1142 visits within 12 months. 1153 1143 "DATA",1130580001.101,55,7) 1154 NQF0086 ^^^^1144 NQF0086 1155 1145 "DATA",1130580001.101,56,0) 1156 MU EP NQF 0088 ^^1146 MU EP NQF 0088 1157 1147 "DATA",1130580001.101,56,1) 1158 1148 Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy … … 1172 1162 one or more office visits within 12 months. 1173 1163 "DATA",1130580001.101,56,7) 1174 NQF0088 ^^^^1164 NQF0088 1175 1165 "DATA",1130580001.101,57,0) 1176 MU EP NQF 0089 ^^1166 MU EP NQF 0089 1177 1167 "DATA",1130580001.101,57,1) 1178 1168 Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care … … 1194 1184 within 12 months. 1195 1185 "DATA",1130580001.101,57,7) 1196 NQF0089 ^^^^1186 NQF0089 1197 1187 "DATA",1130580001.101,58,0) 1198 MU EP NQF 0047 ^^1188 MU EP NQF 0047 1199 1189 "DATA",1130580001.101,58,1) 1200 1190 Asthma Pharmacologic Therapy … … 1212 1202 corticosteroid) or an acceptable alternative treatment 1213 1203 "DATA",1130580001.101,58,7) 1214 NQF0047 ^^^^1204 NQF0047 1215 1205 "DATA",1130580001.101,59,0) 1216 MU EP NQF 0001 ^^1206 MU EP NQF 0001 1217 1207 "DATA",1130580001.101,59,1) 1218 1208 Asthma Assessment … … 1232 1222 symptoms. 1233 1223 "DATA",1130580001.101,59,7) 1234 NQF0001 ^^^^1224 NQF0001 1235 1225 "DATA",1130580001.101,60,0) 1236 MU EP NQF 0002 ^^1226 MU EP NQF 0002 1237 1227 "DATA",1130580001.101,60,1) 1238 1228 Oncology Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breat Cancer … … 1250 1240 reporting period. 1251 1241 "DATA",1130580001.101,60,7) 1252 NQF0002 ^^^^1242 NQF0002 1253 1243 "DATA",1130580001.101,61,0) 1254 MU EP NQF 0385 ^^1244 MU EP NQF 0385 1255 1245 "DATA",1130580001.101,61,1) 1256 1246 Oncology Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients … … 1268 1258 received adjuvant chemotherapy within the 12-month reporting period 1269 1259 "DATA",1130580001.101,61,7) 1270 NQF0385 ^^^^1260 NQF0385 1271 1261 "DATA",1130580001.101,62,0) 1272 MU EP NQF 0389 ^^1262 MU EP NQF 0389 1273 1263 "DATA",1130580001.101,62,1) 1274 1264 Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients … … 1288 1278 any time since diagnosis of prostate cancer. 1289 1279 "DATA",1130580001.101,62,7) 1290 NQF0389 ^^^^1280 NQF0389 1291 1281 "DATA",1130580001.101,63,0) 1292 MU EP NQF 0027 ^^1282 MU EP NQF 0027 1293 1283 "DATA",1130580001.101,63,1) 1294 1284 Smoking Smokers and Tobacco Users to Quit,b. Discussing Smoking and Tobacco use Cessation Medications, c. Discussing Smoking and Tobacco use Cessation Strategies and Tobacco Use Cessation, Medical assistance: a. Advising … … 1308 1298 cessation medications, methods or strategies 1309 1299 "DATA",1130580001.101,63,7) 1310 NQF0027 ^^^^1300 NQF0027 1311 1301 "DATA",1130580001.101,64,0) 1312 MU EP NQF 0055 ^^1302 MU EP NQF 0055 1313 1303 "DATA",1130580001.101,64,1) 1314 1304 Diabetes: Eye Exam … … 1324 1314 exam (no evidence of retinopathy) by an eye care professional 1325 1315 "DATA",1130580001.101,64,7) 1326 NQF0055 ^^^^1316 NQF0055 1327 1317 "DATA",1130580001.101,65,0) 1328 MU EP NQF 0062 ^^1318 MU EP NQF 0062 1329 1319 "DATA",1130580001.101,65,1) 1330 1320 Diabetes: Urine Screening … … 1340 1330 nephropathy. 1341 1331 "DATA",1130580001.101,65,7) 1342 NQF0062 ^^^^1332 NQF0062 1343 1333 "DATA",1130580001.101,66,0) 1344 MU EP NQF 0056 ^^1334 MU EP NQF 0056 1345 1335 "DATA",1130580001.101,66,1) 1346 1336 Diabetes: Foot Exam … … 1356 1346 with monofilament, or pulse exam). 1357 1347 "DATA",1130580001.101,66,7) 1358 NQF0056 ^^^^1348 NQF0056 1359 1349 "DATA",1130580001.101,67,0) 1360 MU EP NQF 0074 ^^1350 MU EP NQF 0074 1361 1351 "DATA",1130580001.101,67,1) 1362 1352 Coronary Artery Disease (CAD): Drug Therapy for Lowering LDLCholesterol … … 1372 1362 on current ACC/AHA guidelines). 1373 1363 "DATA",1130580001.101,67,7) 1374 NQF0074 ^^^^1364 NQF0074 1375 1365 "DATA",1130580001.101,68,0) 1376 MU EP NQF 0084 ^^1366 MU EP NQF 0084 1377 1367 "DATA",1130580001.101,68,1) 1378 1368 Heart Failure (HF): Warfarin Therapy Patients with Atrial Fibrillation … … 1388 1378 who were prescribed warfarin therapy. 1389 1379 "DATA",1130580001.101,68,7) 1390 NQF0084 ^^^^1380 NQF0084 1391 1381 "DATA",1130580001.101,69,0) 1392 MU EP NQF 0073 ^^1382 MU EP NQF 0073 1393 1383 "DATA",1130580001.101,69,1) 1394 1384 Ischemic Vascular Disease (IVD): Blood Pressure Management … … 1420 1410 (<140/90 mmHg). 1421 1411 "DATA",1130580001.101,69,7) 1422 NQF0073 ^^^^1412 NQF0073 1423 1413 "DATA",1130580001.101,70,0) 1424 MU EP NQF 0068 ^^1414 MU EP NQF 0068 1425 1415 "DATA",1130580001.101,70,1) 1426 1416 Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic … … 1446 1436 another antithrombotic during the measurement year 1447 1437 "DATA",1130580001.101,70,7) 1448 NQF0068 ^^^^1438 NQF0068 1449 1439 "DATA",1130580001.101,71,0) 1450 MU EP NQF 0004 ^^1440 MU EP NQF 0004 1451 1441 "DATA",1130580001.101,71,1) 1452 1442 Initiation and Engagement of Alcohol and Other Drug Dependence Treatment:(a)Initiation,(b)Engagement … … 1468 1458 services with an AOD diagnosis within 30 days of the initiation visit. 1469 1459 "DATA",1130580001.101,71,7) 1470 NQF0004 ^^^^1460 NQF0004 1471 1461 "DATA",1130580001.101,72,0) 1472 MU EP NQF 0012 ^^1462 MU EP NQF 0012 1473 1463 "DATA",1130580001.101,72,1) 1474 1464 Prenatal Care: Screening for Human Immunodeficiency Virus (HIV) … … 1484 1474 second prenatal care visit. 1485 1475 "DATA",1130580001.101,72,7) 1486 NQF0012 ^^^^1476 NQF0012 1487 1477 "DATA",1130580001.101,73,0) 1488 MU EP NQF 0014 ^^1478 MU EP NQF 0014 1489 1479 "DATA",1130580001.101,73,1) 1490 1480 Prenatal Care: Anti-D Immune Globulin … … 1500 1490 immune globulin at 26-30 weeks gestation. 1501 1491 "DATA",1130580001.101,73,7) 1502 NQD0014 ^^^^1492 NQD0014 1503 1493 "DATA",1130580001.101,74,0) 1504 MU EP NQF 0018 ^^1494 MU EP NQF 0018 1505 1495 "DATA",1130580001.101,74,1) 1506 1496 Controlling High Blood Pressure … … 1516 1506 the measurement year 1517 1507 "DATA",1130580001.101,74,7) 1518 NQF0018 ^^^^1508 NQF0018 1519 1509 "DATA",1130580001.101,75,0) 1520 MU EP NQF 0032 ^^1510 MU EP NQF 0032 1521 1511 "DATA",1130580001.101,75,1) 1522 1512 Cervical Cancer Screening … … 1530 1520 more Pap tests to screen for cervical cancer 1531 1521 "DATA",1130580001.101,75,7) 1532 NQF0032 ^^^^1522 NQF0032 1533 1523 "DATA",1130580001.101,76,0) 1534 MU EP NQF 0033 ^^1524 MU EP NQF 0033 1535 1525 "DATA",1130580001.101,76,1) 1536 1526 Chlamydia Screening for Women … … 1546 1536 year. 1547 1537 "DATA",1130580001.101,76,7) 1548 NQF0033 ^^^^1538 NQF0033 1549 1539 "DATA",1130580001.101,77,0) 1550 MU EP NQF 0036 ^^1540 MU EP NQF 0036 1551 1541 "DATA",1130580001.101,77,1) 1552 1542 Use of Appropriate Medications for Asthma … … 1564 1554 years, and total). 1565 1555 "DATA",1130580001.101,77,7) 1566 NQF0036 ^^^^1556 NQF0036 1567 1557 "DATA",1130580001.101,78,0) 1568 MU EP NQF 0052 ^^1558 MU EP NQF 0052 1569 1559 "DATA",1130580001.101,78,1) 1570 1560 Low Back Pain: Use of Imaging Studies … … 1580 1570 days of diagnosis. 1581 1571 "DATA",1130580001.101,78,7) 1582 NQF0052 ^^^^1572 NQF0052 1583 1573 "DATA",1130580001.101,79,0) 1584 MU EP NQF 0075 ^^1574 MU EP NQF 0075 1585 1575 "DATA",1130580001.101,79,1) 1586 1576 Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control … … 1604 1594 performed during the measurement year and whose LDL-C<100 mg/dL 1605 1595 "DATA",1130580001.101,79,7) 1606 NQF0075 ^^^^1596 NQF0075 1607 1597 "DATA",1130580001.101,80,0) 1608 MU EP NQF 0575 ^^1598 MU EP NQF 0575 1609 1599 "DATA",1130580001.101,80,1) 1610 1600 Diabetes: Hemoglobin A1c Control (<8.0%) … … 1618 1608 (type 1 or type 2) who had hemoglobin A1c <8.0% 1619 1609 "DATA",1130580001.101,80,7) 1620 NQF0575 ^^^^1610 NQF0575 1621 1611 "DATA",1130580001.101,81,0) 1622 MU EP NQF 0028B ^^1612 MU EP NQF 0028B 1623 1613 "DATA",1130580001.101,81,1) 1624 1614 NQF0028B Preventive Care and Screening Measure Pair: a. Tobacco Use Assessment,b. Tobacco Cessation Intervention … … 1666 1656 NQF0024 2-10Y^^^^^^334^338 1667 1657 "DATA",1130580001.101,83,0) 1668 MU EP NQF 0038 NUM1 DPT ^^1658 MU EP NQF 0038 NUM1 DPT 1669 1659 "DATA",1130580001.101,83,5) 1670 1660 NQF0038 NUM1 DPT … … 1672 1662 NQF0038 NUM1 DPT^^^^^^329^192^11 1673 1663 "DATA",1130580001.101,84,0) 1674 MU EP NQF 0038 NUM2 IPV ^^1664 MU EP NQF 0038 NUM2 IPV 1675 1665 "DATA",1130580001.101,84,5) 1676 1666 NQF0038 NUM2 IPV … … 1678 1668 NQF0038 NUM2 IPV^^^^^^224^192^11 1679 1669 "DATA",1130580001.101,85,0) 1680 MU EP NQF 0038 NUM3 MMR ^^1670 MU EP NQF 0038 NUM3 MMR 1681 1671 "DATA",1130580001.101,85,5) 1682 1672 NQF0038 NUM3 MMR … … 1684 1674 NQF0038 NUM3 MMR^^^^^^183^192^11 1685 1675 "DATA",1130580001.101,86,0) 1686 MU EP NQF 0038 NUM4 HiB ^^1676 MU EP NQF 0038 NUM4 HiB 1687 1677 "DATA",1130580001.101,86,5) 1688 1678 NQF0038 NUM4 HiB … … 1690 1680 NQF0038 NUM4 HiB^^^^^^189^192^11 1691 1681 "DATA",1130580001.101,87,0) 1692 MU EP NQF 0038 NUM5 HEP B ^^1682 MU EP NQF 0038 NUM5 HEP B 1693 1683 "DATA",1130580001.101,87,5) 1694 1684 NQF0038 NUM5 HEP B … … 1696 1686 NQF0038 NUM5 HEP B^^^^^^194^192^11 1697 1687 "DATA",1130580001.101,88,0) 1698 MU EP NQF 0038 NUM6 VZV ^^1688 MU EP NQF 0038 NUM6 VZV 1699 1689 "DATA",1130580001.101,88,5) 1700 1690 NQF0038 NUM6 VZV … … 1702 1692 NQF0038 NUM6 VZV^^^^^^198^192^11 1703 1693 "DATA",1130580001.101,89,0) 1704 MU EP NQF 0038 NUM7 PCV ^^1694 MU EP NQF 0038 NUM7 PCV 1705 1695 "DATA",1130580001.101,89,5) 1706 1696 NQF0038 NUM7 PCV … … 1708 1698 NQF0038 NUM7 PCV^^^^^^205^192^11 1709 1699 "DATA",1130580001.101,90,0) 1710 MU EP NQF 0038 NUM8 HEP A ^^1700 MU EP NQF 0038 NUM8 HEP A 1711 1701 "DATA",1130580001.101,90,5) 1712 1702 NQF0038 NUM8 HEP A … … 1714 1704 NQF0038 NUM8 HEP A^^^^^^208^192^11 1715 1705 "DATA",1130580001.101,91,0) 1716 MU EP NQF 0038 NUM9 RV ^^1706 MU EP NQF 0038 NUM9 RV 1717 1707 "DATA",1130580001.101,91,5) 1718 1708 NQF0038 NUM9 … … 1720 1710 NQF0038 NUM9^^^^^^216^192^11 1721 1711 "DATA",1130580001.101,92,0) 1722 MU EP NQF 0038 NUM10 FLU ^^1712 MU EP NQF 0038 NUM10 FLU 1723 1713 "DATA",1130580001.101,92,5) 1724 1714 NQF0038 NUM10 … … 1726 1716 NQF0038 NUM10^^^^^^331^192^11 1727 1717 "DATA",1130580001.101,93,0) 1728 MU EP NQF 0038 NUM11 COMBO5 ^^1718 MU EP NQF 0038 NUM11 COMBO5 1729 1719 "DATA",1130580001.101,93,5) 1730 1720 NQF0038 NUM11 COMBO5 … … 1732 1722 NQF0038 NUM11 COMBO5^^^^^^228^192^11 1733 1723 "DATA",1130580001.101,94,0) 1734 MU EP NQF 0038 NUM12 COMBO6 ^^1724 MU EP NQF 0038 NUM12 COMBO6 1735 1725 "DATA",1130580001.101,94,5) 1736 1726 NQF0038 NUM12 COMBO6 … … 1738 1728 NQF0038 NUM12 COMBO6^^^^^^231^192^11 1739 1729 "DATA",1130580001.101,95,0) 1740 MU 2011 INP ADV DIRECTIVES ^^1730 MU 2011 INP ADV DIRECTIVES 1741 1731 "DATA",1130580001.101,95,5) 1742 1732 Advance Directives 1743 "DATA",1130580001.101,95,7)1744 ^^^^1745 1733 "DATA",1130580001.101,96,0) 1746 MU 2011 INP CPOE ^^1734 MU 2011 INP CPOE 1747 1735 "DATA",1130580001.101,96,5) 1748 1736 CPOE for Medications 1749 "DATA",1130580001.101,96,7)1750 ^^^^1751 1737 "DATA",1130580001.101,97,0) 1752 MU 2011 INP MED RECON ^^1738 MU 2011 INP MED RECON 1753 1739 "DATA",1130580001.101,97,5) 1754 1740 Medication Reconcilliation 1755 "DATA",1130580001.101,97,7)1756 ^^^^1757 1741 "DATA",1130580001.101,98,0) 1758 MU 2011 INP PROBLEM LIST ^^1742 MU 2011 INP PROBLEM LIST 1759 1743 "DATA",1130580001.101,98,5) 1760 1744 Problem List 1761 "DATA",1130580001.101,98,7)1762 ^^^^1763 1745 "DATA",1130580001.101,99,0) 1764 MU 2011 INP VITAL SIGNS ^^1746 MU 2011 INP VITAL SIGNS 1765 1747 "DATA",1130580001.101,99,5) 1766 1748 Record Vital Signs 1767 "DATA",1130580001.101,99,7)1768 ^^^^1769 1749 "DATA",1130580001.101,100,0) 1770 MU 2011 INP SMOKING STATUS ^^1750 MU 2011 INP SMOKING STATUS 1771 1751 "DATA",1130580001.101,100,5) 1772 1752 Smoking Status 1773 "DATA",1130580001.101,100,7)1774 ^^^^1775 1753 "DATA",1130580001.101,101,0) 1776 MU 2011 INP MED LIST ^^1754 MU 2011 INP MED LIST 1777 1755 "DATA",1130580001.101,101,5) 1778 1756 Active Medication List 1779 "DATA",1130580001.101,101,7)1780 ^^^^1781 1757 "DATA",1130580001.101,102,0) 1782 MU 2011 INP ALLERGY LIST ^^1758 MU 2011 INP ALLERGY LIST 1783 1759 "DATA",1130580001.101,102,5) 1784 1760 Medication Allergy List 1785 "DATA",1130580001.101,102,7)1786 ^^^^1787 1761 "DATA",1130580001.101,103,0) 1788 MU 2011 INP DEMOGRAPHICS ^^1762 MU 2011 INP DEMOGRAPHICS 1789 1763 "DATA",1130580001.101,103,5) 1790 1764 Record Demographics 1791 "DATA",1130580001.101,103,7)1792 ^^^^1793 1765 "DATA",1130580001.101,104,0) 1794 1766 MU EP NQF 0024 11-17Y … … 2545 2517 "FRV1K",1130580001.101,"94,7",9,1) 2546 2518 MU NQF0038 CHILDREN'S IMMUNIZATIONS 2519 "IX",1130580001.101,1130580001.101,"B",0) 2520 1130580001.101^B^New-Style B Index. Will be used as part of the key.^R^^F^IR^I^1130580001.101^^^^^LS 2521 "IX",1130580001.101,1130580001.101,"B",1) 2522 S ^C0Q(101,"B",$E(X,1,30),DA)="" 2523 "IX",1130580001.101,1130580001.101,"B",2) 2524 K ^C0Q(101,"B",$E(X,1,30),DA) 2525 "IX",1130580001.101,1130580001.101,"B",2.5) 2526 K ^C0Q(101,"B") 2527 "IX",1130580001.101,1130580001.101,"B",11.1,0) 2528 ^.114IA^1^1 2529 "IX",1130580001.101,1130580001.101,"B",11.1,1,0) 2530 1^F^1130580001.101^.01^30^1^F 2547 2531 "IX",1130580001.101,1130580001.101,"MU",0) 2548 2532 1130580001.101^MU^MEANINGFUL USE YEAR KEY^R^^F^IR^I^1130580001.101^^^^^LS … … 2557 2541 "IX",1130580001.101,1130580001.101,"MU",11.1,1,0) 2558 2542 1^F^1130580001.101^.3^30^1^F 2543 "KEY",1130580001.101,1130580001.101,"A",0) 2544 1130580001.101^A^P^562 2545 "KEY",1130580001.101,1130580001.101,"A",2,0) 2546 ^.312IA^1^1 2547 "KEY",1130580001.101,1130580001.101,"A",2,1,0) 2548 .01^1130580001.101^1 2549 "KEYPTR",1130580001.101,1130580001.101,"A") 2550 1130580001.101^B 2559 2551 "MBREQ") 2560 2552 0 … … 2586 2578 ^9.49I^1^1 2587 2579 "PKG",215,22,1,0) 2588 1.0^3120731^312080 2^82580 1.0^3120731^3120806^8 2589 2581 "PKG",215,22,1,"PAH",1,0) 2590 3^312080 32582 3^3120806^8 2591 2583 "PKG",215,22,1,"PAH",1,1,0) 2592 ^^155^155^312080 32584 ^^155^155^3120806 2593 2585 "PKG",215,22,1,"PAH",1,1,1,0) 2594 2586 Summary … … 3002 2994 3003 2995 "^DD",1130580001.101,1130580001.101,0,"VRPK") 3004 QUALITY MEASURES 2996 C0Q 3005 2997 "^DD",1130580001.101,1130580001.101,.01,0) 3006 2998 NAME^RF^^0;1^K:$L(X)>30!($L(X)<1)!'(X'?1P.E) X
Note:
See TracChangeset
for help on using the changeset viewer.
